West Pharmaceutical(US:WST) Prnewswireยท2025-06-13 09:45Core Viewpoint - A class action securities lawsuit has been filed against West Pharmaceutical Services, Inc. alleging securities fraud that affected investors between February 16, 2023, and February 12, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that West Pharmaceutical Services made false statements regarding its customer demand visibility and attributed headwinds to temporary COVID-related product destocking, while in reality, it was facing significant ongoing destocking in its high-margin HVP portfolio [3]. - It is alleged that West's SmartDose device, which was marketed as a high-margin growth product, actually diluted the company's profit margins due to operational inefficiencies [3]. - The margin pressures from these issues raised the risk of costly restructuring activities, including the company's exit from continuous glucose monitoring contracts with long-standing customers [3]. - As a result of these factors, the positive statements made by the defendants about the company's business, operations, and prospects were materially false and/or misleading [3]. Group 2: Next Steps for Investors - Investors who suffered losses in West Pharmaceutical Services during the specified timeframe have until July 7, 2025, to request to be appointed as lead plaintiff in the case [4]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for aggrieved shareholders and has extensive expertise in complex securities litigation [5]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [5].